Drug intelligence / Profile preview

LipoBloc

Development stage: Unknown
Lead developer: UMeWorld
Modality: Small Molecules
Administration: Oral

Overview

LipoBloc is a phytosterol-based dietary supplement developed by AlphaRx for the management of elevated cholesterol levels. The product utilizes a proprietary clinical delivery system consisting of lecithin micelles to enhance the solubility and bioavailability of phytosterols compared to traditional powder forms. Phytosterols work by competitively binding to cholesterol absorption sites in the small intestine, thereby reducing the absorption of dietary and biliary cholesterol and lowering serum total and LDL cholesterol levels. Clinical data suggests that this micellar delivery method significantly improves the efficacy of cholesterol absorption reduction.

Brand names: LipoBloc
Other names: phytosterols

Targets

NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on LipoBloc.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LipoBloc.

Explore the full profile